About the Study

Kidney Disease (FSGS, Alport syndrome, IgA nephropathy): A clinical trial of sparsentan treatment for kidney diseases

Travere Therapeutics, Inc. (the Sponsor) is running a research study to see if a study drug, not yet approved for use by the United States Food and Drug Administration (FDA), named sparsentan, will help in the treatment of kidney diseases and if it is safe to use in people.

Interested in learning more?

Full Study Name: EPPIK - Sparsentan drug study for children with FSGS, Alports, and IGA